Apraclonidine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Apraclonidine
Therapeutic Class: Antiglaucoma Agent
Subclass: Alpha-2 Adrenergic Agonist (Ophthalmic)
Speciality: Ophthalmology
Schedule (India): Schedule H
Route(s): Ophthalmic (topical use only)
Formulations Available in India:
- Ophthalmic solution 0.5% (5 mL bottle)
- Ophthalmic solution 1% (available as unit-dose or 5 mL bottle — limited availability)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Short-term adjunctive therapy in open-angle glaucoma or ocular hypertension (when IOP is inadequately controlled with other agents)
→ Apraclonidine 0.5% ophthalmic solution
| Parameter | Detail |
| Starting dose | 1 drop in affected eye(s) three times daily |
| Titration | Not applicable — fixed dosing regimen |
| Usual maintenance dose | 1 drop in affected eye(s) three times daily |
| Maximum dose | 1 drop TID; do not exceed this frequency |
| Duration |
Short-term only — limit to a maximum of 30 days
|
| Key clinical notes | Tachyphylaxis (loss of IOP-lowering effect) commonly develops within 1 month. Not suitable for long-term monotherapy. Reassess IOP response within 1–2 weeks. If inadequate response or tolerance develops, switch to alternative agents. |
2. Prevention and control of acute IOP elevation following anterior segment laser procedures (e.g., argon laser trabeculoplasty, Nd:YAG laser iridotomy, laser capsulotomy)
→ Apraclonidine 1% ophthalmic solution
| Parameter | Detail |
| Pre-procedure dose | 1 drop in the operative eye, approximately 1 hour before the laser procedure |
| Post-procedure dose | 1 drop in the same eye immediately upon completion of the procedure |
| Titration | Not applicable — single pre- and post-procedure use |
| Usual maintenance dose | Not applicable (peri-procedural use only) |
| Maximum dose | 2 drops total (1 pre + 1 post per procedure per eye) |
| Key clinical notes | Effectively blunts the acute IOP spike that commonly occurs within 1–4 hours post-laser. Not intended for continued use beyond the day of the procedure. |
Secondary Indications — Adults Only (Off-label, if any)
1. Diagnosis of Horner syndrome — OFF-LABEL
- Use: 1 drop of apraclonidine 0.5% instilled in both eyes; observe for reversal of anisocoria (dilation of the miotic pupil in the affected eye due to denervation supersensitivity)
- Duration: Single diagnostic use
- Specialist only: Neuro-ophthalmologist supervision recommended
- Evidence basis: Multiple published case series and international neuro-ophthalmology practice; widely accepted diagnostic test. Not an CDSCO-approved indication.
No other well-documented off-label indications for adult use in Indian practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
No CDSCO-approved paediatric indication exists. Paediatric use is based on specialist clinical judgement.
→ Elevated IOP in paediatric glaucoma (congenital or juvenile) — short-term adjunctive use
(Paediatric ophthalmologist supervision mandatory)
(Paediatric ophthalmologist supervision mandatory)
| Parameter | Detail |
| Minimum age | Not recommended below 6 years of age (risk of significant systemic absorption and CNS depression in younger children) |
| Starting dose | 1 drop of 0.5% solution in affected eye(s) two to three times daily |
| Titration | Not applicable |
| Usual maintenance dose | 1 drop TID |
| Maximum dose | 1 drop TID; do not exceed 30 days of continuous use |
| Safety monitoring | Monitor for systemic effects at each visit: somnolence, lethargy, bradycardia, hypotension, pallor, hypothermia. Check heart rate and blood pressure at baseline and within 1 week of starting. |
⚠ Contraindicated in infants below 1 year of age — high risk of CNS depression, apnoea, and cardiovascular compromise due to immature blood-brain barrier and higher systemic absorption.
Secondary Indications — Paediatric Doses (Off-label, if any)
1. Pharmacological diagnosis of Horner syndrome in children — OFF-LABEL
- Dose: 1 drop of 0.5% solution in both eyes; observe pupillary response after 30–45 minutes
- Minimum age: Can be used in children ≥1 year under specialist supervision
- Specialist only: Paediatric neuro-ophthalmologist supervision
- Evidence basis: International case series; accepted diagnostic test in paediatric neuro-ophthalmology practice
Not recommended below 1 year of age for any indication except under close specialist supervision in a monitored setting.
RENAL ADJUSTMENT
No dose adjustment required for topical ophthalmic use. Systemic absorption following ocular instillation is minimal.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | No dose adjustment required |
| Moderate impairment | No dose adjustment required; use with routine monitoring |
| Severe impairment | Use with caution — although systemic absorption is low, clonidine-like compounds undergo hepatic metabolism; monitor for any systemic effects (hypotension, bradycardia) |
CONTRAINDICATIONS
- Known hypersensitivity to apraclonidine, clonidine, or any component of the formulation (including benzalkonium chloride)
- Concurrent use with monoamine oxidase inhibitors (MAOIs) — risk of hypertensive crisis
- Infants below 1 year of age — significant risk of CNS depression, apnoea, and cardiovascular compromise
- Severe or unstable cardiovascular disease (e.g., recent myocardial infarction, decompensated heart failure, haemodynamically significant arrhythmias)
CAUTIONS
- Cardiovascular disease (including controlled hypertension, coronary artery disease, cerebrovascular disease) — monitor blood pressure and heart rate
- History of vasovagal episodes
- Chronic renal impairment — although systemic absorption is low, exercise caution in severe renal failure
- Depression or other psychiatric disorders — alpha-2 agonists may worsen depressive symptoms
- Concurrent use with CNS depressants or alcohol — additive sedation risk
- Raynaud phenomenon or thromboangiitis obliterans
- Contact lens wearers — remove lenses before instillation; wait at least 15 minutes before reinserting (formulation contains benzalkonium chloride, which can be absorbed by soft contact lenses)
- Elderly patients — increased susceptibility to systemic effects
- Tendency to develop tachyphylaxis — reassess IOP response within 2 weeks
PREGNANCY
| Parameter | Detail |
| Overall safety | Insufficient human data; avoid during pregnancy unless benefit clearly outweighs risk |
| Teratogenicity | No adequate human studies; animal data limited |
| Preferred alternatives in Indian practice | Topical timolol (most clinical experience in pregnancy for IOP control); topical dorzolamide may be considered in 2nd/3rd trimester. Avoid prostaglandin analogues (theoretical risk of uterine contractions) |
| When it may be used | Only if other approved topical agents fail or are contraindicated; ophthalmologist and obstetrician joint decision |
| What to monitor | Maternal blood pressure and heart rate; fetal heart rate monitoring if chronic use is unavoidable |
LACTATION
| Parameter | Detail |
| Compatibility | Caution advised — insufficient data on excretion into human breast milk |
| Expected drug levels in milk | Expected to be low (minimal systemic absorption from topical ocular route) |
| Preferred alternatives | Topical timolol (more data available in lactation, though infant monitoring still needed); topical dorzolamide or brinzolamide may be considered |
| What to monitor in infant | Sedation, lethargy, poor feeding, bradycardia, hypotonia |
| Note | Brimonidine should be used with caution during breastfeeding as it may cause infant CNS depression — not necessarily a safer choice than apraclonidine in this setting |
ELDERLY
- Recommended starting dose: Same as adults (1 drop 0.5% TID for glaucoma; standard peri-procedural dosing for laser)
- Titration: Not applicable (fixed dosing); however, consider starting with BID frequency and assessing tolerability before moving to TID
- Extra risks:
-
- Increased susceptibility to systemic hypotension and bradycardia
- Higher incidence of allergic blepharoconjunctivitis
- Greater risk of drug interactions with concurrent cardiovascular medications
- Monitor blood pressure and pulse rate at initiation and follow-up visits
- Assess for dizziness or orthostatic symptoms that may increase fall risk
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Risk | Action |
|
MAOIs (phenelzine, isocarboxazid, tranylcypromine, selegiline at high doses)
|
Risk of severe hypertensive crisis or potentiation of CNS effects |
Contraindicated — do NOT combine
|
|
Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline)
|
May blunt the IOP-lowering and hypotensive effect of apraclonidine; unpredictable cardiovascular response |
Avoid combination if possible; if co-prescribed, monitor IOP response closely
|
|
Systemic clonidine or other centrally-acting alpha-2 agonists (methyldopa, tizanidine)
|
Additive systemic hypotension, bradycardia, and CNS depression |
Avoid concurrent use unless under close monitoring
|
|
Opioids, benzodiazepines, or other potent CNS depressants
|
Additive sedation and CNS depression, particularly in elderly or paediatric patients |
Use with caution; monitor for excessive sedation
|
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Risk | Action |
| Topical or systemic beta-blockers (timolol, atenolol, metoprolol) | Additive IOP-lowering (beneficial) but also additive risk of bradycardia and hypotension | Monitor heart rate and blood pressure; combination is commonly used in ophthalmology but warrants vigilance |
| Systemic antihypertensive agents (ACE inhibitors, ARBs, calcium channel blockers) | Potential synergistic hypotensive effect due to alpha-2 agonist activity | Monitor blood pressure, especially during initial days of combination |
| Cardiac glycosides (digoxin) | Apraclonidine-induced bradycardia may be additive with digoxin effect on AV conduction | Monitor heart rate |
| Topical ophthalmic agents with preservatives | Additive ocular surface irritation if multiple preserved drops are used concurrently | Space administration by at least 5 minutes between different eye drops |
COMMON ADVERSE EFFECTS
Ocular (most frequent):
- Conjunctival blanching or pallor (due to local vasoconstriction)
- Ocular pruritus and discomfort
- Foreign body sensation
- Lid retraction (upper lid)
- Tearing or dryness
- Mydriasis (mild)
Systemic:
- Dry mouth
- Dry nose
- Fatigue and drowsiness
- Headache
- Altered taste
SERIOUS ADVERSE EFFECTS
- Allergic blepharoconjunctivitis — occurs in up to 30–50% of patients with use beyond 1 month; presents as periocular dermatitis, lid oedema, follicular conjunctival reaction → discontinue immediately and switch class
- Systemic hypotension and/or bradycardia — especially in elderly, cardiovascular-compromised patients, or with concomitant antihypertensives → monitor vitals; discontinue if symptomatic
- CNS depression (somnolence, lethargy, apnoea) — particularly dangerous in neonates and infants → contraindicated below 1 year
- Contact dermatitis of the periocular skin (delayed hypersensitivity) → discontinue permanently
- Severe ocular inflammation (rare) → discontinue and evaluate for alternative aetiology
MONITORING REQUIREMENTS
Baseline (before starting):
- Intraocular pressure measurement
- Cardiovascular history and current medications review
- Baseline heart rate and blood pressure (especially in elderly and patients on antihypertensives)
- Slit-lamp examination of anterior segment
After initiation (within first 1–2 weeks):
- IOP re-check to confirm adequate response (tachyphylaxis may begin early)
- Assess for signs of ocular allergy (redness, lid swelling, itching)
- Monitor heart rate and blood pressure in vulnerable patients (elderly, children, cardiovascular disease)
Ongoing / Long-term (if used beyond 2 weeks):
- Reassess at 2–4 weeks for tachyphylaxis (loss of ≥50% of initial IOP-lowering effect indicates need to switch)
- Monitor for allergic blepharoconjunctivitis — examine lids, conjunctiva at each visit
- In paediatric patients: assess systemic symptoms (somnolence, feeding, behaviour) at each follow-up
- Do not continue beyond 30 days unless exceptional circumstances under specialist supervision
BRANDS AVAILABLE IN INDIA
- Iopidine 0.5% eye drops (Alcon Laboratories) — limited availability; may require special order
- Iopidine 1% eye drops (Alcon Laboratories) — limited availability; primarily stocked in tertiary eye care centres
(Note: Alphagan/Alphagan-P is brimonidine, NOT apraclonidine — do not confuse. No known fixed-dose combinations of apraclonidine are marketed in India.)
PRICE RANGE (INR)
- Iopidine 0.5% (5 mL): Approximately ₹120–160 per bottle (prices may vary based on availability and region)
- Iopidine 1%: Approximately ₹140–180 per unit (limited distribution)
- Not listed under NLEM; not NPPA price-controlled
- Availability may be inconsistent; confirm stock with pharmacy or distributor before prescribing
CLINICAL PEARLS
- Time-limited agent: Restrict use of 0.5% formulation to a maximum of 30 days. Tachyphylaxis and allergic blepharoconjunctivitis are the rule, not the exception, with prolonged use — plan a switch strategy from the outset.
- Peri-laser use is the strongest indication: The 1% formulation is most useful as a single pre- and post-procedure instillation to blunt acute IOP spikes after anterior segment laser. This remains its most reliable clinical role.
- Do not confuse with brimonidine: Both are alpha-2 agonists, but brimonidine is suitable for long-term IOP control, while apraclonidine is not. Brimonidine also has neuroprotective properties and a lower tachyphylaxis rate.
- Allergic reaction = permanent stop: If periocular dermatitis, lid oedema, or follicular conjunctivitis develops, discontinue apraclonidine permanently and switch to a different drug class. Do not rechallenge.
- Absolute contraindication in neonates and young infants: Risk of life-threatening CNS and respiratory depression. For paediatric glaucoma in infants, topical timolol (at reduced concentration, e.g., 0.25%) under specialist care is a safer alternative.
- Horner syndrome diagnosis: Apraclonidine 0.5% is a widely used pharmacological test — reversal of anisocoria in the affected eye confirms postganglionic sympathetic denervation. This off-label use is an important clinical application in neuro-ophthalmology.
TAGS
apraclonidine; antiglaucoma; alpha-2 agonist; ophthalmic; IOP spike; peri-laser; short-term use; Horner syndrome; tachyphylaxis; Schedule H; ophthalmology
VERSION
RxIndia v0.1 — 14 Feb 2026
REFERENCES
- CDSCO: Iopidine 0.5% and 1% ophthalmic solution (Alcon) — approved product
- IP/NFI: Apraclonidine listed in ophthalmic preparations
- NLEM: Not listed
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics (alpha-2 agonist pharmacology, ocular pharmacology chapter)
- API Textbook of Medicine (glaucoma management overview)
- AIIMS Ophthalmology department protocols (peri-laser IOP management; supportive reference)
- Indian Journal of Ophthalmology — clinical reviews on alpha-2 agonist use in glaucoma (supportive)
- International case series on apraclonidine for Horner syndrome diagnosis (off-label indication; clearly marked)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.